Nanogen to Host Second Quarter Conference Call August 14, 2008

Nanogen, Inc. (Nasdaq:NGEN), developer of innovative, high-quality diagnostic products, will host a conference call on Thursday, August 14, 2008 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2008 second quarter results. The financial results press release will be issued at market open on August 14, 2008. Interested investors and others may participate in the conference call by dialing 866.362.5158 for US/Canada participants and 617.597.5397 for international participants. The conference ID will be 66510183. Audio of management's presentation will be available via live webcast on the investor relations section of Nanogen's corporate website at www.nanogen.com, and will be archived for one year. A digital recording of the call will also be available for two weeks, beginning two hours after the completion of the conference call on August 14, and can be accessed via telephone at 888-286-8010 for US/Canada participants and 617-801-6888 for international participants. The conference ID, 72452328, will be required to listen to the playback. About Nanogen, Inc. Nanogen (Nasdaq:NGEN) has a strong product and proprietary technology base of diagnostic solutions for two of the fastest growing in vitro diagnostic (IVD) markets—molecular diagnostics and rapid point-of-care testing. The company provides their innovative, high-quality diagnostic products to clinicians and physicians worldwide, making it easier to predict and diagnose diseases, ultimately improving patient care. Products include molecular diagnostic kits and reagents, and kits for rapid, point-of-care testing. Nanogen has pioneered research in areas involving biomedical markers, molecular biology and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen’s website at www.nanogen.com. Nanogen Forward-Looking Statement This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.